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Neuronal ceroid lipofuscinoses (NCL) comprise a group of inherited lysosomal disorders with variable age of
onset, characterized by lysosomal accumulation of autoﬂuorescent ceroid lipopigments, neuroinﬂammation,
photoreceptor- and neurodegeneration. Most of the NCL-related genes encode soluble and transmembrane
proteins which localize to the endoplasmic reticulum or to the endosomal/lysosomal compartment and di-
rectly or indirectly regulate lysosomal function. Recently, exome sequencing led to the identiﬁcation of
four novel gene defects in NCL patients and a new NCL nomenclature currently comprising CLN1 through
CLN14. Although the precise function of most of the NCL proteins remains elusive, comprehensive analyses
of model organisms, particularly mouse models, provided new insight into pathogenic mechanisms of NCL
diseases and roles of mutant NCL proteins in cellular/subcellular protein and lipid homeostasis, as well as
their adaptive/compensatorial regulation at the transcriptional level. This review summarizes the current
knowledge on the expression, function and regulation of NCL proteins and their impact on lysosomal integ-CSPα
Progranulin rity. This article is part of a Special Issue entitled: The Neuronal Ceroid Lipofuscinoses or Batten Disease.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
The neuronal ceroid lipofuscinoses (NCLs) are inherited progressive
degenerative diseases that primarily affect the brain and retina. They
are considered lysosomal storage disorders (LSD), because of their char-
acteristic accumulation of autoﬂuorescent ceroid lipopigments, subunit
c of mitochondrial ATP synthase or sphingolipid activator proteins A
and D in lysosomes of most cells. In contrast to classical LSDs that are
caused by dysfunctional lysosomal enzymes or transporters, resulting
in the notable lysosomal accumulation of undegraded substrates orme-
tabolites, respectively [1], the rather heterogenous storage material in
NCLs is not clearly disease-speciﬁc. Therefore, the determination of
the primary substrates/metabolites possibly accumulating in NCLs
may ﬁrst require the elucidation of the functions of NCL-causing gene
products. The onset of clinical symptoms and subsequent classiﬁcation
range from prenatal/perinatal, infantile and juvenile to adult forms of
the diseases [2]. However, the clinical features of dementia, physical
deterioration, seizures and visual failure, that eventually lead to earlyronal Ceroid Lipofuscinoses or
, Children's Hospital, University
us, Martinistrasse 52, 20246
9 40 741058504.
l rights reserved.death and blindness, are common to all NCLs [3]. Thirteen genetically
distinct NCL variants, categorized by age of onset and pathological fea-
tures, have been identiﬁed. NCL-causing mutated proteins (CLN1 to
CLN14) represent soluble lysosomal enzymes, polytopic membrane
proteins localized in lysosomes or in the ER, or synaptic vesicle associat-
ed proteins (Table 1). Since the function of most of the CLN proteins
or their natural substrates are unknown, system biology approaches in-
cluding genome-wide analyses, proteomics as well as bioinformatics
have been applied in studies on cultured patient cells or various animal
models of NCLs that revealed new and unpredicted interactions with
CLN proteins and improved understanding of the molecular mecha-
nisms of NCL diseases. The availability of mouse models for many
NCL diseases (reviewed by C. Russell et al., this issue) also enabled
research on experimental therapies such as gene or small molecule-
based therapies.
This review summarizes our current knowledge on the expression,
protein-chemical properties and post-translationalmodiﬁcations, the in-
tracellular transport, subcellular localization, proposed function of the
NCL-causing gene products, and their interactions with other proteins.
The reader is also referred to recent reviews [4–9], and to other reviews
in this issue (by Mink et al.; Williams et al., Kousi et al.) summarizing
clinical courses, nomenclature and genetic variability in NCL
diseases, experimental approaches to deﬁne the functions of NCL
gene products, and the development of various model organisms to
gain insight into pathogenic mechanisms of NCL diseases.
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2.1. CLN1/PPT1 gene and protein expression
CLN1 encodes palmitoyl protein thioesterase 1, PPT1 [10], an en-
zyme that removes palmitate groups from S-acylated proteins [11].
The CLN1 transcript is ubiquitously expressed [12–15]. The abundance
of CLN1mRNA in several regions of human and rodent brain is develop-
mentally regulated starting early in embryonic life [13,16,17]. The
nascent PPT1 polypeptide contains 306 amino acids, including a 25
amino acid signal sequence which is co-translationally cleaved [12].
Mature PPT1 migrates as a ~37/35 kDa doublet, and is N-glycosylated
at N197, N212, N232 in a manner essential for the activity, stability,
and trafﬁcking of the protein [12,18–20]. The crystal structure of bovine
PPT1, which is 94% identical to the human homologue, shows the glob-
ularmonomeric structure with classicalα/β serine hydrolase fold and a
catalytic triad composed of S115, H289, and D233 [18]. Recently, a
structural basis for the effect of CLN1mutants was constructed showing
that mutations associated with a total loss of enzymatic activity affect
the core region of the enzyme, whereas less severe mutations are local-
ized at the surface of PPT1 [21]. Whereas native substrates of PPT1-
mediated depalmitoylation activity are unknown, several in vitro tar-
gets have been reported, including H-Ras, palmitoyl-CoA, α subunits
of heterotrimeric G proteins, neuron-speciﬁc GAP43 and rhodopsin
[11,22,23]. The expression of PPT1 inmouse brain preparations and cul-
tured neurons parallels with the abundance of presynaptic marker pro-
tein and indicates a role for PPT1 in synaptogenesis [13,24]. Studies on
the intracellular targeting of PPT1 andmannose 6-phosphate proteome
analyses suggested that PPT1 is targeted to lysosomal compartments
via a mannose 6-phosphate receptor-mediated pathway [23,25–27].
However, several ﬁndings indicate that the localization and functional
activity of PPT1 is not limited to lysosomes, especially in neurons. First,
enzymatic activity of PPT1 shows a substrate-dependent neutral pH op-
timum unusual for lysosomal enzymes which may suggest functionality
in extralysosomal compartments [22]. Second, PPT1 has been demon-
strated to partly associate with lipid raft domains [28] and third, both
overexpressed and endogenous PPT1 have been observed in vesicular
structures in the soma, dendrites, and axonal varicosities [13,24,29–32].
The localization of PPT1 in synaptic vesicles, however, is a matter of de-
bate [24,29,31,33]. The difference in processing and trafﬁcking of PPT1
between non-neuronal and neuronal cell types further highlights puta-
tive distinct functions of PPT1 in neurons [20]. Interestingly, a substantial
amount of overexpressed PPT1 is secreted in neural and extraneural
cells, and therefore, it has been speculated that the protein may also
have substrates/functions in extracellular space [12,29].
2.2. CLN1/PPT1 protein function and interactome
Early changes in the pathogenesis in Ppt1−/− mice involve break-
down of axons and synapses [34], and PPT1 has been implicated in
the recycling of synaptic vesicles. This was based on the observations
of a reduced total and readily releasable synaptic vesicle pool size, and
persistent membrane anchorage of the palmitoylated presynaptic pro-
teins SNAP-25, VAMP-2, and syntaxin 1 in cultured cortical neurons
and brain specimens of Ppt1−/−mice, and post-mortem brain samples
of CLN1 disease patients [30,33]. The expression and co-localization of
PPT1 with a glutamate receptor subunit, NMDAR2B, was enhanced
after kainic acid-induced excitotoxicity suggesting a role for PPT1 in syn-
aptic plasticity and protection from excitotoxicity [32]. Furthermore,
altered sensitivity of cultured Ppt1−/− neurons to excitotoxicity caused
by AMPA- and NMDA-treatments have been reported, and link PPT1 to
glutamate receptor functions [35]. However, no fundamental alterations
in the electrophysiological properties of Ppt1−/− and Ppt1Δex4-derived
neurons have been observed, except a progressive decrease in the fre-
quency of miniature synaptic currents in Ppt1−/− mice [33,36]. Addi-
tionally, studies with Drosophila melanogaster have further contributedto deﬁning the role of PPT1 in axonal and synaptic compartments.
Ppt1−/−-ﬂy shows reduced lifespan but no apparent neurodegener-
ative phenotype in adulthood [37]. However, analyses on Ppt1-deﬁcient
ﬂy embryos suggest thatDrosophila Ppt1 is required for proper neuronal
development, including processes of neuronal cell fates and organiza-
tion, and axon guidance [38]. Furthermore, loss-of-function and gain-
of-function modiﬁer screens for genes interacting with Ppt1 have
implied a connection between Ppt1 and endosomal/synaptosomal
trafﬁcking, and synaptic growth, as well as in lipid metabolism and in-
tracellular signaling [39–41]. In addition, a genetic interaction between
Ppt1 and Psd, a protein involved in autophagosomal clearance of accu-
mulated rhodopsin, an in vitro substrate of PPT1, has been observed in
D. melanogaster [42].
Phenotypic analysis of Schizosaccharomyces pombe deﬁcient for
Pdf1, a yeast orthologue of PPT1, suggests a function for PPT1 in mod-
ulation of lysosomal/vacuolar protein sorting and pH [43] which is
supported by increased lysosomal pH values measured in ﬁbroblasts
of Finnish CLN1 patients [44]. Furthermore, trafﬁcking of endocytosed
material in Finnish CLN1 patient ﬁbroblasts was observed to be defec-
tive at the level of late endosomes/lysosomes [45].
Several studies found that changes in the levels of PPT1 expression
correlated with the activation of caspase-mediated apoptotic path-
ways in neuroblastoma cells and lymphoblasts [46–48], which appear
to be caused by ER and oxidative stress [49–51]. More recently, PPT1
has been suggested to function in negative regulation of tumor necro-
sis factor (TNF)-induced pathway of apoptosis possibly via modulat-
ing the speciﬁc membrane domain association of TNF receptors via
depalmitoylation [52].
Abnormalities in the number, intracellular localization pattern and
morphology ofmitochondria, aswell as defects in themitochondrial en-
zyme activities and adaptive energymetabolism have been observed in
patient ﬁbroblasts, sheep, Ppt1−/− mice, and Caenorhabditis elegans
[53–56] which could not be conﬁrmed, however, in Ppt1Δex4 mice [57].
PPT1 has been repeatedly associated with lipid metabolism. Post-
mortem brain samples of CLN1 disease patients revealed changes in
phospholipid content. Severe loss of phospholipids due to neuron
loss and demyelination were shown to be accompanied by abnormal-
ities in remaining phospholipid content [58]. Ceramide levels of lipid
rafts have been reported to be decreased in PPT1 overexpressing CHO
cells most likely due to the fact that PPT1 is involved in the processing
of saposin D, a storage component in CLN1 disease, and involved in
ceramide catabolism [28,45]. Additionally, an increase in cholesterol
biosynthesis and a direct link to apolipoprotein A-I metabolism have
been observed in Ppt1Δex4 mice [36,57]. PPT1 interacts with andmod-
ulates the cell surface levels of F1 complex of ATP synthase, a protein
originally found in the mitochondria but recently also shown to act as
a receptor for apolipoprotein A-I/HDL at the plasma membrane [59].
Furthermore, Ppt1-deﬁcient mouse cortical neurons showed increased
amounts of F1 complex at the plasma membrane and consistently, in-
creased apolipoprotein A-I uptake accompanied by abnormalities in
serum lipid/lipoprotein proﬁles of Ppt1Δex4 mice [57]. Further analyses
are required to determine the localization of this PPT1 interaction.
3. CLN2
3.1. CLN2/TPP1 gene and protein expression
The CLN2 gene encodes the tripeptidyl peptidase 1 (TPP1, CLN2),
originally identiﬁed as an abundant 46 kDa mannose 6-phosphorylated
protein that was absent in the brain specimens from late infantile NCL
patients [60]. The CLN2 gene is expressed ubiquitously in human, rat
and mouse tissues and is developmentally regulated [61–64]. TPP1 is
a lysosomal serine protease that removes tripeptides from the N-
terminus of small polypeptides [65]. It is synthesized as an inactive 66/
67 kDa precursor protein consisting of a 19 amino acid signal peptide, a
176 amino acid prosegment and a 368 amino acid catalytically active
Table 1
NCL-related proteins, their molecular characteristics, postulated function, interactions and lipid phenotype.
NCL-related
protein name
Other names/
synonyms
Protein size and
structural
features
Posttranslational
modiﬁcation
Protein localization Function Interactions Abnormal lipid
compositiona
CLN1 Palmitoyl protein thioesterase 1
(PPT1)
306 aa,
soluble protein
N-gly
M6P
Lysosomal matrix,
extralysosomal vesicules,
extracellular
Palmitoylthioesterase S-acetylated proteins (GAP43, rhodopsin,
saposin D)
Phospholipids,
ceramide, cholesterol
CLN2 Tripeptidyl peptidase 1 (TPP1) 563 aa,
soluble protein
N-gly
M6P
Lysosomal matrix Serine protease CLN3, CLN5 n.d.
CLN3 – 438 aa,
6 TM protein
N-gly
farnesylated
phosphorylated
Late endosomal/lysosomal
membrane, presynaptic
vesicles
Unknown; modulation of vesicular
trafﬁcking and fusion,
pH regulation
Hook1, Rab7, fodrin, kinesin-2, CLN5,
Na+, K+ATPase
BMP, Phospholipids,
galactosyl-ceramide
CLN4 Cysteine-string protein alpha
(CSPα), DNAJC5
198 aa,
soluble protein
Palmitoylated Cytosolic, associated to
vesicular membranes
Hsc70 co-chaperone, involved in exocytosis
and endocytosis
CSPα, Hsp70, Hsp40, Hsp90, HIP, HOP, SGT,
SNAP-25, dynamin-1, syntaxin, Gαs, Rab3b,
synaptotagmin 9, myosin IIB, calsenilin,
DHHC17
n.d.
CLN5 – 407 aa,
soluble protein
N-gly
M6P
Lysosomal matrix Unknown; modulation of vesicular
trafﬁcking predicted
PPT1/CLN1, TPP1/CLN2, CLN3, CLN6, CLN8 Sphingolipids
CLN6 – 311 aa,
7 TM protein
None ER-membrane Unknown CLN5, CLN6
CRMP-2
Phospho- and
glycosphingo-lipids,
cholesterol
CLN7 – 518 aa,
12 TM protein
N-gly
proteolytic cleaved
Lysosomal membrane Unknown; transmembrane transporter
function predicted
AP-1, cathepsin L n.d.
CLN8 – 286 aa,
5 TM protein
None ER/ERGIC-membrane Unknown; regulation in lipid metabolism
predicted
CLN5, CLN8, VAPA, GATE16, syntaxin 8 Ceramides,
phospholipids,
sphingolipids,
sulfatides
CLN9
(postulated)
Unknown – – – Unknown, role in ceramide synthesis
postulated
– Ceramide,
sphingomyelin,
sphingolipids,
globosides
CLN10 Cathepsin D (CTSD) 462 aa, soluble
protein
N-gly
M6P
Lysosomal matrix,
extracellular
Aspartyl endopeptidase APP, CST3, CTSB, proSAP, and several others BMP, cholesterol,
phospho- and
sphingolipids
CLN11 Progranulin, proepithelin,
acrogranin
593 aa,
soluble protein
None Extracellular Unknown, roles in inﬂammation,
embryogenesis, cell motility and
tumorigenesis postulated
MMPs, ADAMs, TGFα receptors, sortilin,
ADAMTS-7/ADAMTS-12/perlecan/HDL/
COMP
n.d.
CLN12 ATPase 13A2, KRPPD, PARK9,
HSA9947,
RP-37C10.4
1180 aa,
10 TM protein
None Lysosomal membrane Unknown; regulation of ion homeostasis
postulated
Interaction to 43 proteins involved in
vesicular trafﬁcking and synuclein
misfolding postulated
n.d.
CLN13 Cathepsin F (CTSF) 484 aa,
soluble protein
N-gly
M6P
Lysosomal matrix Cysteine protease CD47 antigen n.d.
CLN14 Potassium channel
tetramerization
domain-containing protein 7
(KCTD7)
289 aa,
soluble protein
Phosphorylated Cytosolic, partially
associated to membranes
Unknown; modulation of ion channel
activity predicted
Cullin-3, KCTD7 n.d.
aa, amino acids, TM, transmembrane domains, M6P, mannose 6-phosphate, N-gly, N-glycosylation, BMP, bis(monoacylglycero)phosphate, n.d., not described.
a In addition to the common lipopigment storage.
1868
K
.K
ollm
ann
et
al./
Biochim
ica
et
Biophysica
A
cta
1832
(2013)
1866
–1881
1869K. Kollmann et al. / Biochimica et Biophysica Acta 1832 (2013) 1866–1881mature form [66–68]. The analysis of TPP1 crystal structure [69] con-
ﬁrmedmutational data indicating that S475 is the active site nucleophile,
and E272 and D276 are involved in the catalytic reaction [65,70]. TPP1 is
N-glycosylated and during passage to the Golgi apparatus two of the high
mannose-type oligosaccharides at N210, N222 and eventually N286 are
modiﬁed with mannose 6-phosphate residues [67,71,72]. The mannose
6-phosphate residues allow binding and lysosomal targeting of TPP1
precursor by mannose 6-phosphate receptors with a higher preference
for the cation-dependent mannose 6-phosphate receptor [73]. Proper
N-glycosylation in particular at N286 is critical for lysosomal
targeting, processing and enzymatic activity of TPP1 [72,74,75]. The de-
livery of TPP1 to lysosomes is accompanied by cleavage of the
prosegment either by autoactivation [65] or another serine protease
[67]. It has been shown that the prosegment acts as an inhibitor of the
mature enzyme [69,76]. Interestingly, polyanionic glycosaminoglycans
(GAGs) have been shown to increase the rates of activation even at
higher pH values and partially protect themature enzyme against alka-
line pH and thermal denaturation which might be important for extra-
cellular functions of TPP1 [77].
3.2. CLN2/TPP1 protein function and interactome
The identity of natural TPP1 substrates are not known, but several
peptide hormones such as angiotensin II [78], glucagon [79], substance
P [78], cholecystokinin and neuromedin [79,80], as well as synthetic
amyloid-β-peptides [78] and the mitochondrial ATP synthase subunit
c [66] were cleaved by TPP1 in vitro. None of these in vitro substrates,
however, are found in the CLN2 storage material. Additionally, apopto-
sis has been linked to CLN2 function since CLN2-defective ﬁbroblasts
are resistant to TNF-induced apoptosis and CLN2 can catalyze the cleav-
age of Bid, a Bcl-2 interacting protein in vitro [81].
Increased amounts of TPP1 protein have been described in various
pathological conditions such as neurodegenerative lysosomal storage
disorders, inﬂammation, cancer and aging (reviewed in [79]). TPP1
activity is signiﬁcantly elevated in CLN3 and CLN5 diseases and the
proteins have been reported to interact with CLN2. However, the
physiological relevance of the interactions has remained elusive [82].
4. CLN3
4.1. CLN3 gene and protein expression
CLN3 encodes a 438-amino acid 43 kDa type III transmembrane
protein which has cytoplasmic N- and C-termini, six membrane-
spanning segments, and an amphipathic helix in one of the lumenal
loops [83–87]. CLN3 exhibits tissue-dependent glycosylation patterns
[84]. Among several potential glycosylation sites N71 and N85 have
been validated experimentally [88]. N-glycosylation is not required for
trafﬁcking of CLN3 [88,89] but may be functionally important [90].
CLN3 can be farnesylated at the C-terminal CAAX motif. Farnesylation
creates an additional, C-terminal loop into the protein, and affects the
delivery of CLN3 via enhancing the sorting of the protein in early
endosomal compartments [88]. CLN3 also contains several putative
phosphorylation sites, and it has been reported that a green ﬂuorescent
protein-taggedCLN3 can acquire radiolabeledphosphate that is alkaline
phosphatase-sensitive [87,91]. Additionally, a potential N-terminal
myristoylation site of CLN3 has been reported but has not been vali-
dated experimentally [83,84,92].
A detailed tissue expression pattern and intracellular localization
of CLN3 has been challenging to determine, because of low protein
levels and a lack of suitable antibodies. mRNA and protein expression
analyses indicate that CLN3 is ubiquitously expressed in the human
body [83,84,93–95]. Analyses of Cln3-deﬁcient reporter mice express-
ing β-galactosidase under the native Cln3 promoter have provided
novel information on the spatiotemporal protein expression of Cln3, es-
pecially in the nervous system [96–98]. The abundance of Cln3 in neuraltissues is relatively low [83,84,93,98,99]. The expression of Cln3 in var-
ious brain regions is most prominent during postnatal development
[96]. In non-neuronal cells, CLN3 primarily resides in late endosomes/
lysosomes ([100], reviewed in [101]). The transport of CLN3 to lyso-
somes occurs slowly [88], and requires at least three different sorting
signals. A dileucine signal (LI) proceeded by an acidic patch is located
in the large cytoplasmic loop [85,102]. However, whether the LI signal
of CLN3 is recognized by adaptor proteins AP-1 andAP-3,which areme-
diators of Golgi to endo-lysosomal transport [102,103], remains contro-
versial. The dileucine signal and additional targetingmotifs, a stretch of
methionine and glycine separated by nine amino acid residues [M(X)9G
motif] in the C-terminal domain, and prenylation of CLN3, are required
for efﬁcient sorting and transport of CLN3 to lysosomal compartments
[85,88,102]. In neuronal cells, a substantial fraction of CLN3 is addition-
ally targeted to neuronal extensions and synaptosomeswhere it has been
found to reside in early endosomes, presynaptic vesicles, and in so far
unidentiﬁed vesicles [85,104–106].
4.2. CLN3 protein function and interactome
CLN3 has no fundamental homologywith other proteins or functional
domains, except a distant similarity with equilibrative nucleoside trans-
porter family SLC29 and fatty acid desaturases [107,108]. It is highly con-
served across species [92,109], and human CLN3 is able to complement
functions of its orthologues [110–112]. However, computational analyses
have predicted that Saccharomyces cerevisiae and S. pombe orthologues of
CLN3, termed Btn1p, might produce different topologies than the human
protein [87]. Furthermore, it has been suggested that Btn1p is predomi-
nantly located within the Golgi apparatus [113,114].
Based on extensive research of over 17 years with various mamma-
lian systems, yeast and invertebrate models, CLN3 has been implicated
in various intracellular processes. CLN3 may have an important role in
the maturation and fusion of autophagosomes, endo-lysosomal com-
partments, and possibly axonal vesicles. It affects the steady-state posi-
tion andmotility of late endosomes/lysosomes [104,115], and late steps
of the endocytic pathway [116] most likely via interactions with Hook1
and microtubular motor protein complexes, namely Rab7/RILP/ORP1L/
dynein–dynactin and kinesin-2 [115,116]. Interactions between
CLN3 and Rab7/motor protein complexes may also explain why
maturation of autophagosomes is impaired in Cln3-deﬁcient mice
and CLN3 disease patients. Defective autophagosomal maturation
due to CLN3 deﬁciency was suggested to result from defects in
the movement of autophagosomes to the lysosomal fusion sites
[117]. Interestingly, a Rab7/motor protein complex has been
reported to affect the microtubular transport of autophagic vesi-
cles [118]. Rab7 and possibly another CLN3-interacting protein,
fodrin [119], also play a role in the vesicular trafﬁcking along the
axons that may support neurite outgrowth [120–123]. Therefore it
is likely that CLN3 is part of the fast axonal transport machinery [124].
Several studies indicate that CLN3 may also be involved in retrograde
transport from late endosomes to Golgi. Btn1p as well as the yeast
orthologue of CLN3-interacting Hook1, Btn2p, are involved in late
endosome-to-Golgi transport of Yif1p [114,125]. While Btn2p localizes
to vacuoles and associates there with retrieval components, Btn1p pos-
sibly regulates SNARE complex phosphorylation and assembly at the
Golgi membranes [114,125]. Whethermammalian CLN3 has similar ac-
tivities has remained unresolved. CLN3 has been reported to interact
with other NCL proteins, including CLN5 [82,126], and recent ﬁndings
on CLN5 imply that the CLN5/CLN3 interaction might be relevant
for the endosome-to-Golgi retrograde trafﬁcking [127]. In addition,
dysregulated ﬂuid-phase endocytosis [104,117] and impaired exit
of mannose 6-phosphate receptor from TGN [128] have been ob-
served in CLN3-deﬁcient cells.
CLN3 also appears to play a role in the actin/myosin-associated
functions and the microtubular system. Primary mouse embryonic ﬁ-
broblasts and surviving Purkinje cells of Cln3−/−mice exhibit defects
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which are most likely due to functional disturbances in the interac-
tion between CLN3 and non-muscle myosin IIB [129]. Further, CLN3
interacts with fodrin and Na+, K+ ATPase, and plasma membrane-
association of the fodrin cytoskeleton and subunits of Na+, K+ ATPase
are affected in CLN3 patient ﬁbroblasts and Cln3−/− mouse neurons
[119]. These data suggest a role for CLN3 in fodrin-mediated process-
es at synaptic compartments, and in non-pumping functions of Na+,
K+ ATPase ([119] and references therein). Na+, K+ ATPase is also
directly involved in the regulation of glutamatergic neurotransmis-
sion [131,132] and therefore, it is possible that glutamate receptor-
mediated excitotoxicity observed in CLN3 disease mouse models
[133,134] may result from loss of functional CLN3–Na+, K+ ATPase
interaction. CLN3 has also been reported to possess anti-apoptotic
functions which are, at least partially, mediated via an interaction
with calsenilin, a mediator of a Ca2+-induced cell death ([135] and
references therein). In CLN3-deﬁcient mice and patients changes in
neurotransmitter system [133,134,136–139], autoantibodies against
glutamic acid decarboxylase (GAD65), an enzyme that converts the
excitatory neurotransmitter glutamate to the inhibitory neurotrans-
mitter GABA [140], and death of GABAergic neurons have been reported
[141,142]. These data suggest that CLN3 may contribute to modulation
of components involved in neurotransmission.
The view that CLN3 is also involved in lipidmetabolism emerged from
studies showing that CLN3 expression correlates with palmitoyl-protein
Δ9-desaturase activity [108] and synthesis of bis(monoacylglycero)
phosphate (BMP; also termed lysobisphosphatidic acid, LBPA) [143].
Furthermore, alterations in the phospholipid levels and their subcel-
lular distribution have been reported in Btn1p-deﬁcient S. cerevisiae
[144]. CLN3 has also been implied to affect the raft morphology and
galactosylceramide transport from Golgi to the plasma membrane [145].
Loss of CLN3 has also been reported to affect the integrity of oxidative
stress response pathway [146] accompanied by the accumulation of
mitochondrial proteins, changes in the mitochondrial size and
morphology, activity of mitochondrial enzymes, and low abundance
of high-energy phosphate compounds ([104,147] and references
therein). These observations suggest functional links between CLN3
and mitochondria.
Based on studies with patient ﬁbroblasts and other human cell lines,
as well as Btn1p-deﬁcient yeast cells, CLN3 also seems to contribute to
maintenance of lysosomal size and pH homeostasis [44,110,148–151]
that might involve the general stress-response protein Sdo1, a yeast
orthologue of Shwachman–Bodian–Diamond syndrome protein (SBDS).
Lysosomes/vacuoles from CLN3 patient lymphoblasts and Btn1p-
deﬁcient yeast also exhibit decreased lysosomal import of arginine
resulting in multiple disturbances in cellular arginine metabolism
[111,152,153]. Btn1p-deﬁcient cells further exhibit limited synthesis
of nitric oxide and suppression of nitric oxide-dependent signaling
pathways, likely due to the fact that arginine serves as the substrate
for nitric oxide synthesis [154]. Moreover, Btn1p-deﬁcient S. pombe
shows defects in cell-wall structure, cytokinesis, distribution of sterol-
rich domains, Golgi morphology, and sorting of the vacuolar hydrolase
carboxypeptidase Y (Cpy1p) [110,113,155,156].
While a null mutation in CLN3 exhibits no obvious external pheno-
type in D. melanogaster, over-expression of the protein led to a pheno-
type resembling the Notch loss-of-function phenotype, being more
severe when Notch signaling-pathway was challenged [157]. Based
on the ﬁnding that Notch signaling appears unaffected downstream of
Notch cleavage, it was suggested that increased levels of CLN3 most
likely impair the processing or cleavage of the Notch receptor itself
[157]. A CLN3-expressingﬂy has also been used to systematically screen
for genes that modify CLN3-dependent phenotypes. Several intracellu-
lar processes or pathways emerged from the screens, including stress
response signaling and regulation of mRNA translation and localization
[157,158]. By comparative genome-wide expression analyses in lym-
phocytes of CLN3 patients with the same 1 kb deletion but differentprogression rates of the disease, several potential modiﬁer genes were
identiﬁed which play important roles in various signaling pathways
[159]. The validation and the physiological signiﬁcance of these
dysregulated genes in CLN3-defective cells and their impact on the dis-
ease progression remain to be investigated.
5. CLN4
CLN4was originally used to cover all adult onset forms of NCL: adult
onset exhibiting autosomal dominant (Parry disease) or recessive in-
heritance (Kufs disease). For Kufs disease presented with progressive
myoclonus epilepsy (type A) mutations in the CLN6 gene have been
identiﬁed [160,161] whereas for Kufs disease with dementia and motor
disturbances (type B) mutations in the CTSF gene were described (see
below). The molecular basis of the dominant form of adult NCL, Parry
disease, has been identiﬁed by two disease-causing mutations in the
DNAJC5 gene encoding cysteine-string protein alpha (CSPα) [162,163],
and it is this form that is now covered by the gene symbol CLN4 and is
thus referred to as CLN4 disease.
5.1. CSPα gene and protein expression
In situ hybridization studies in rat brain revealed DNAJC5 mRNA
expression throughout the brain with the highest levels in the cerebel-
lum and hippocampus, in CA regions and dentate gyrus [164]. The CSPα
protein has been primarily localized on synaptic vesicles in neurons ac-
counting for 1% of total vesicle protein [165], but also on secretory gran-
ules in various endocrine, neurocrine and exocrine cells [166].
5.2. CSPα protein function and interactome
CSPα is a highly conserved protein of 198 amino acids that forms
detergent-resistant dimers. It is composed of three domains, the
N-terminal “J”-domain (aa 14–83), a linker domain (aa 84–112), the
cysteine-string domain (aa 113–135), and a C-terminal domain (aa
136–198) [166]. Themutations in CSPα, L115R and L116del, occurwithin
the highly conserved cysteine-string region that is responsible for mem-
brane binding/targeting and oligomerization [162]. In addition, CSPα is
extensively palmitoylated on a central cysteine-rich “string-domain”
containing 14 cysteines in a stretch of 25 amino acids which is required
for initial membrane targeting [167]. The “J”-domain is highly homolo-
gous to a region of the bacterial chaperone protein DnaJ. CSPα functions
as molecular co-chaperone and activates the ATPase activity of 70 kDa
heat-shock cognate (Hsc70). CSPα forms a trimeric complex with the
small glutamine-rich tetratricopeptide repeat domain protein (SGT) for
ATP-dependent folding of the t-SNARE protein SNAP-25 [164,168].
Another substrate of the CSPα–Hsc70 chaperone complex represents
the GTPase dynamin-1 regulating synaptic vesicle endocytosis [169].
In presynaptic terminals SNARE complex assembly and disassembly be-
tween SNAP-25, syntaxin-1 and synaptobrevin-2 are required during
repeated rounds of exo- and endocytosis of synaptic vesicles. Analysis
of Cspα-deﬁcient mice demonstrated that the loss of SNAP-25
chaperoning impaired the SNARE complex assembly and led to an ex-
cess of highly reactive syntaxin-1 and synaptobrevin-2 followed by in-
appropriate protein interactions that may damage the nerve terminals
[170]. Of note, overexpression of α-synuclein, a small presynaptic
protein linked to Parkinson disease, ameliorates the phenotype of
CSPα-deﬁcient mice [171]. These ﬁndings imply that in neuronal syn-
apses, the structurally different α-synuclein and CSPα act within
the same pathway but excluding a direct functional redundancy. The
analysis of Cspα-deleted Drosophila showed neurodegeneration and
a reduction in neurotransmitter release associated with an intracellu-
lar rise in Ca2+ concentration [172] suggesting a role of CSPα in
Ca2+-triggered exocytosis [173]. Recordings, however, in the Calyx
of Held synapse of Cspα-deﬁcient mice found no evidence for
Cspα-dependent Ca2+ channel function or Ca2+-regulated vesicle
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normal at birth but developed progressive loss of synapses and
neurodegeneration with paralysis which were evident after 2 to
3 weeks of life and is lethal after 2 to 4 months [174]. Of interest,
synapses in Cspα-deﬁcient mice that ﬁre more frequently are lost
ﬁrst [175]. Additionally, Cspα-deﬁcient mice show a massive and
rapid degeneration of photoreceptor synapses that starts before
eye opening and results in blindness [176]. These ﬁndings suggest
that repeated ﬁring and multiple rounds of synaptic vesicle cycles lead
to misfolding of SNAP-25 and dynamin-1 which are degraded or form
aggregates in CSPα-defective neurons. Unbiased systematic proteomic
approaches, identiﬁed 22 proteins whose levels were decreased
in CSPα-deﬁcient synaptosomes and may represent potential sub-
strates for the CSPα–Hsc70 chaperone complex [169]. The physiological
relevance of these proteins in the pathogenesis of CLN4 remains to be
determined. Recently, expression analyses revealed that mutant CSPα
is mistargeted and forms aggregates induced and maintained by
palmitoylation [177]. The authors also provided evidence that CSPα di-
rectly interacts with the palmitoyltransferase DHHC 17. The ability
ofmutant CSPα to induce co-aggregation ofwild-type CSPα [177] offers
a possible mechanism for the dominant negative effect of mutant CSPα
protein in neurons of CLN4 patients.
In addition to the CSPα–Hsc70 chaperone complex substrates
SNAP-25 and dynamin-1, several proteins have been identiﬁed that
bind to CSPα such as syntaxin, Gαs, Rab3b and synaptotagmin 9 [178]
but it is unknown whether they represent substrates of the chaperone
complex. In cooperation with other chaperones such as 40 kDa heat-
shock protein (Hsp40), Hsp90, Hsc70 interacting protein (HIP), and
Hsp70 organizing protein (HOP), CSPα ensures functionality of synap-
ses ([164], reviewed in [7]).
6. CLN5
6.1. CLN5 gene and protein expression
Cln5 mRNA is ubiquitously expressed in mouse, human brain and
peripheral organs [16,179]. In mouse brain, Cln5 expression has been
reported at embryonic day E13 and increases gradually up to postna-
tal day 30, suggesting developmental regulation. The most abundant
expression of Cln5 transcripts has been observed in cerebral cortex,
cerebellum, and in the ganglionic eminence of the embryonic mouse
brain. In the adult brain, the most intense signal can be detected
in the Purkinje cell layer of the cerebellum, in the cerebral cortex,
as well as in the hippocampal principal cell layers [179]. Cln5 gene
expression differs between neurons and glia. High expression in mi-
croglia and the very early microglial activation in Cln5 deﬁcient mice
suggest a role for CLN5 in microglial function [180].
The CLN5 gene encodes a 407 amino acid polypeptide with a pre-
dicted molecular mass of 46 kDa [181]. Human CLN5 contains four
initiator methionines, M1, M30, M50 andM62, and in vitro translation
analyses have demonstrated synthesis of four polypeptides with ap-
parent molecular masses ranging from 39 to 47 kDa [82,182]. Expres-
sion analysis in BHK cells suggests that translation occurs from M62
[182] followed by cleavage of the signal peptide (M62 to G95).
CLN5 has been shown to be a highly glycosylated soluble lysosomal
protein and three of the eight potential N-linked glycans at N320,
N330 and N401 contain M6P residues [71,182–185]. The mouse
Cln5 is a soluble lysosomal glycoprotein with prominent homology
to human CLN5 and the Cln5 knockout mouse develops typical symp-
toms of an NCL disease [179,186].
6.2. CLN5 protein function and interactome
The function of CLN5 is unknown and no sequence homology to
other proteins has been described. CLN5 interaction partners have
been identiﬁed utilizing in vitro binding and co-immunoprecipitationanalyses. CLN5 appears to interact with many of the known NCL pro-
teins like PPT1/CLN1, TPP1/CLN2, CLN3, CLN6 and CLN8 [82,185].
Of these, the CLN5–CLN1 interaction is remarkable since the lysosomal
localization of themost common CLN5mutant Y392X, can be restored by
co-expressing CLN1/PPT1, further supporting the interaction of these two
NCL proteins [82,126]. Additionally, CLN1 and CLN5 bind F1-ATPase in
vitro [126], implicating mitochondrial involvement or defects in lipid
transport. A defective sphingolipid transport has also been demonstrated
in peritoneal macrophages of the Cln5 knockout mouse [180]. Recent
studies have given further clues to CLN5 function by showing that
intralysosomal CLN5 is required for the recruitment of Rab7 and subse-
quently of the retromer complex required for endosome-to-Golgi traf-
ﬁcking, on the cytoplasmic face of endosomal membranes to enhance
the efﬁcient sorting of the cargo receptor sortilin to the Golgi apparatus
[127]. Since CLN3 has been shown to bind directly to Rab 7 [115] it
seems that inmammalian cells both CLN3 andCLN5 affect cooperatively
the retrograde trafﬁcking from endosomes. Finally, comparative gene
expression proﬁling of Cln1 and Cln5 knockout mouse brains have
suggested common defective pathways linked to neuronal growth cone
stabilization [187].
7. CLN6
7.1. CLN6 gene and protein expression
CLN6 transcripts are ubiquitously expressed in all adult human
and mouse tissues [188,189], with differences in various regions of
the developing brain [190]. On the cellular level the highest concen-
trations of Cln6 mRNA have been observed in cortical layers II–VI, in
the Purkinje cell layer, dentate gyrus and hippocampal pyramidal
cell layer of the CA1 region [190].
The CLN6 protein is a highly conserved membrane protein of 311
amino acids [188,189] which is localized in the endoplasmic reticu-
lum [191,192]. The N-terminal cytoplasmic 49 amino acids and the
distal pair of transmembrane domains 6 and 7 contain combinatorial
motifs for ER retention of CLN6 [193]. No posttranslational modiﬁca-
tions have been detected on the 27 kDa CLN6 protein. The half-life of
CLN6 was estimated to be >30 h, whereas the rate of synthesis and
the stability of mutant CLN6 proteins are reduced due to nonsense-
mediated mRNA decay and proteasomal degradation, respectively
[194–196]. There was no evidence for ER stress or activation of un-
folded protein response in the brain of Cln6-defective (nclf) mice
[196].
7.2. CLN6 protein function and interactome
The function of CLN6 is unknown, and no sequence homology
to other proteins has been described. It is not clear, how mutant
CLN6 leads to lysosomal dysfunction characterized by accumulation
of autoﬂuorescent lipopigments, subunit c ofmitochondrial ATP synthase,
free cholesterol and phospho- and glycosphingolipids in lysosome-
derived storage bodies [196–201]. Furthermore, increased numbers of
autophagic vacuoles and marker proteins of autophagosomes in cul-
tured neuronal cells and brain tissue indicate an upregulation of this
degradative pathway for damaged organelles and aggregated proteins
or impairment of autophagosome–lysosome fusion [196,197]. Neither
transport nor processing of newly synthesized lysosomal proteins nor
lysosomal enzyme activities or the composition of M6P-containing
lysosomal proteins were affected in CLN6-defective ﬁbroblasts or human
brain [26,191]. The ﬂuid phase dextran endocytosis and receptor-
mediated uptake of a recombinant lysosomal enzyme, however, was im-
paired [191,197] which might be related to alterations in endosomal/
lysosomal pH measured in ﬁbroblasts of putative CLN6 patients [44].
In CLN6-defective ﬁbroblasts and neuronal cells the concentration of the
mitochondrial manganese-dependent superoxide dismutase (MnSOD
or SOD2) was found to be speciﬁcally increased, whichmight be caused
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kines [202].
Several interactions of CLN6 with other proteins have been identi-
ﬁed, providing some clues on the role of CLN6 in the cell, in particular
brain cells, during the course of the disease. First, upon overexpression
CLN6 can form homodimers [193]. Second, pull-down experiments re-
vealed that CLN5 binds among others to CLN6, suggesting the existence
of an NCL protein network that might be important for lysosomal traf-
ﬁcking [126]. A third interaction has been reported between CLN6 and
collapsing response mediator protein-2 (CRMP-2) which is involved
in microtubule assembly and cytoskeletal dynamics during axonal out-
growth. The CRMP-2 protein level is reduced in the thalamus of nclf
mice, which might be associated with the abnormal maturation of nclf
hippocampal neurons in vitro [203].
Another approach to gain insight into the function of CLN6 and
pathophysiological mechanisms underlying the disease is the analysis
of transcript proﬁles. In ﬁbroblast cell lines of ﬁve CLN6 patients 15
genes were found to be dysregulated which are involved in choles-
terol homeostasis, extracellular matrix remodeling, cell signaling
and immuno/inﬂammatory responses [201]. In cultured cerebellar
cells of nclf mice 718 changed transcripts were determined which re-
vealed in gene ontology analysis no obvious functional overlaps with
the gene expression pattern of Cln3-defective cerebellar cells [197].
The data suggest that CLN6 is important for ER function and protein
synthesis, in particular, of membrane receptor proteins. The impact of
dysregulated genes for CLN6 protein and lysosome functions in more
complex in vivo systems awaits further studies.
8. CLN7
8.1. CLN7 gene and protein expression
The CLN7 protein is encoded by the MFSD8 gene which is ubiqui-
tously expressed in several alternative splice variants [204]. In situ hy-
bridization showed that CLN7 transcripts are present throughout the
rat brain with highest concentrations in the granular layer of the cer-
ebellar cortex and the pyramidal layer of the hippocampus which cor-
relates with the distribution of degenerated neurons in CLN7 patients
[204,205]. In cultured rat brain cells the CLN7 mRNA level was found
to be 6- and 12-fold higher in neuronal cells than in astrocytes and
microglial cells, respectively [205].
CLN7 is a highly conserved lysosomalmembraneprotein of 518 amino
acids with 12 predicted transmembrane domains [204]. The human and
mouse CLN7 proteins are N-glycosylated at N371 and N376, and N372,
N377, and N389, respectively, in the luminal loop 9, responsible for the
broad immunoreactive CLN7 polypeptides detectable in western blots
[205,206]. Substitution of theN-glycosylation sites did not affect the lyso-
somal localization. An acidic dileucine motif in the cytosolic N-terminal
domain and tandem tyrosine-based signals in the C-terminal domainme-
diate the direct transport of CLN7 from the Golgi-apparatus to the
endosomal compartment as well as the indirect targeting via the plasma
membrane and the subsequent internalization by clathrin-coated vesicles
[205,206]. Pull-down experiments revealed that the N-terminal dileucine
motif interacts with the tetrameric AP-1 adaptor protein, mediating the
direct transport route of CLN7 [205]. None of the expressed pathogenic
mutations identiﬁed in CLN7 patients disturbed the trafﬁcking and lyso-
somal localization [204,205,207,208]. Upon arrival in lysosomes, CLN7 is
proteolytically cleaved twice proximal and distal to the N-glycosylation
sites in the luminal loop 9 [208]. The formation of the non-glycosylated
36 kDa CLN7 fragment is catalyzed by the lysosomal cysteine protease ca-
thepsin L. This fragment binds strongly to CLN7 [208].
8.2. CLN7 protein function and interactome
The function of CLN7 is unknown but based on sequence homology
CLN7 belongs to the large and diverse major facilitator superfamily(MFS) of secondary active transporters [209]. In vertebrate species a
single orthologue of CLN7 exists, whereas in invertebrates 2 to 18 sim-
ilar proteins were identiﬁed. These proteins unidirectionally transport
small substrates across membranes using electrochemical gradients,
or function as antiporters, transporting two substrates in opposite
directions. Among others, inorganic and organic cations, sugars and
sugar phosphates, drugs, neurotransmitter, and amino acids have
been described to be transported by an individual MFS member with
stringent speciﬁcity. The function and substrate speciﬁcity of CLN7 re-
main to be investigated. This will be a prerequisite to determine the
functional signiﬁcance of the proteolytic processing of CLN7 [208]. The
cleavage of other lysosomal membrane proteins, such as heparan sul-
phate acetyl-CoA α-glucosaminide N-acetyltransferase, mucolipin, or
MFS transporter DIRC2, by lysosomal cysteine proteases have been
reported to affect their function [210–212].
Brain mRNA level of CLN7 appears to be regulated both by acute
dietary iron loading and chronic iron accumulation in Hfe−/− mice,
a model of hemochromatosis [213,214]. It remains to be investigated
whether perturbations in iron homeostasis are associated with the
neuronal expression and function of CLN7.
9. CLN8
9.1. CLN8 gene and protein expression
Mutations in CLN8 cause a variant of late infantile NCL [215] and the
“progressive epilepsy with mental retardation” (EPMR) variant of NCL,
also known as Northern epilepsy [216,217]. The murine Cln8 gene is
mutated in “motor neuron degeneration” (mnd) mice, a naturally oc-
curring mouse model for NCL [216]. Alternative splicing in the 3′UTR
of the CLN8 gene produce three RNA transcripts that show a ubiquitous
tissue distribution in embryonic and adult tissues [216,218]. In prenatal
embryos murine Cln8 mRNA is most prominently expressed in the de-
veloping gastrointestinal tract, dorsal root ganglia and brain. In postna-
tal brain the highest expression is found in the cortex and hippocampus
[218].
The CLN8 gene product is a 286-amino acid non-glycosylated
polytopic transmembrane protein that can form dimers [193,216]. The
33 kDa CLN8 protein localizes to ER and partially to the ER-Golgi inter-
mediate compartment (ERGIC) in non-neuronal and neuronal cells
[219,220] and recycles between ER and ERGIC using an ER-retrieval
signal (KKRP) in its cytoplasmatic C-terminus [219]. Patient mutations
do not affect the ER localization. In polarized epithelial CaCo-2 cells a
basolateral localization of CLN8 was observed and after fractionation
of mouse brain tissue endogenous mouse Cln8 was detectable in light
membrane fractions, different fromER, suggesting that CLN8may locate
outside the ER or in a specialized subcompartment of the ER in polarized
cells [220].
9.2. CLN8 protein function and interactome
The function of the CLN8 protein has not been resolved yet and it
is unclear how mutations in this ER resident protein lead to the accu-
mulation of storage material in lysosomes.
CLN8 belongs to a protein superfamilywith TLC (TRAM–Lag1p–CLN8)
domains. Members of this protein family have been shown to facilitate
translocation of newly synthesized membrane proteins into the ER and
export glycosylphosphatidylinositol-anchored proteins out of the ER
[221]. Other family members are proposed to have a role in sensing,
trafﬁcking, biosynthesis, and metabolism of lipids or function as
acyl-CoA-dependent ceramide synthases in yeast and in mammalian
cells [222–224]. Lipidomic analysis on cerebral brain samples from
EPMR patients showed reduced levels of ceramide, galactosyl- and
lactosylceramide and sulfatide as well as a decrease in long fatty
acyl chain containing molecular species within the sphingolipids,
suggesting a role of CLN8 in ceramide synthesis or regulation of
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metabolism and an impaired transport of lipids from the ER to
ER-related mitochondria-associated membranes were also observed
in mnd mice [226,227] resulting in galactolipid deﬁciency and de-
layed myelin maturation [228].
Additionally induction of ER stress [229], reduced mitochondrial
Ca2+ buffering capacity [230], oxidative stress and alteration of gluta-
mate neurotransmission have been proposed to play an important
role in the pathogenesis promoting neurodegeneration in mnd mice
[231–234].
CLN8 has been shown to form homodimers [193] and bind GST-
CLN5 in pulldown experiments [126]. The biological signiﬁcance of
both interactions is unclear yet.
Additionally, the phenotype of CLN9-deﬁcient cells can be partially
complemented by CLN8 expression, linking CLN8 to ceramide synthesis
and indicating a related function of CLN8 to the putative CLN9 protein
[235]. Furthermore, several potential protein interacting partners of
CLN8, such as the vesicle-associated membrane protein-associated
protein A (VAPA), the Golgi-associated ATPase enhancer of 16 kDa
(GATE16) or syntaxin 8, have been identiﬁed using the split-ubiquitin
membrane yeast-two-hybrid system [236]. These interacting proteins
link CLN8 to the synthesis and transport of lipids, vesicular/membrane
trafﬁcking, autophagy and apoptosis and might allow insights into its
pathophysiological role in cells. In a recent study, CLN8 was identiﬁed
as a candidate modiﬁer gene for Gaucher disease GD1. Therefore it is
thought that Cln8 may function as a protective sphingolipid sensor
and/or in glycosphingolipid trafﬁcking [237].
10. CLN9
10.1. CLN9 protein function and interactome
CLN9 disease has been described in patients with a clinical pheno-
type similar to CLN3, but the gene causing CLN9 disease is unknown
[238]. Gene expression analysis of these unclassiﬁed NCL cases showed
a striking similarity in their gene expression patterns but sets them
apart from other NCL types.
CLN9-deﬁcient ﬁbroblasts are characterized by rounded cell bodies
and prominent nucleoli, cell adhesion defects, and increased sensitivity
to apoptosis [238]. Expression of genes involved in cell adhesion and
apoptosis were dysregulated [238]. A strong decrease of ceramide and
sphingomyelin levels, lactosylceramide, ceramide trihexoside, and
globoside levels were observed in CLN9-deﬁcient ﬁbroblast [238]. The
increase in serinepalmitoyl transferase (SPT) activity designated apertur-
bation of sphingolipidmetabolism resulting from a defect in the ceramide
synthesis [238].
A second study on CLN9-deﬁcient cells showed that the low
ceramide levels did not result from mutations in genes for β-1,4-
galactosyltransferases, GB3/CD77 synthase and sphingomyelin synthases
or from defects in the ceramide trafﬁcking from the endoplasmatic retic-
ulum to Golgi, but from a decrease in dihydroceramide synthase activity
[235]. The human dihydroceramide synthase is not well characterized.
Overexpression of the gene Lag1 that is necessary for ceramide synthesis
in yeast, and its human homologues LASS1 and CLN8, that comprise Lag1
sequence homology, could partially complement the CLN9 phenotype
with regard to ceramide levels, growth, and apoptosis. However, nomu-
tations were found in LASS1–LASS6 and in CLN8 in patient ﬁbroblasts
[235].
11. CLN10
11.1. CLN10 gene and protein expression
Mutations in the cathepsin D gene (CTSD, CLN10) cause neuronal
ceroid-lipofuscinosis with congenital or juvenile onset. The CTSD
gene is ubiquitously expressed in most mammalian tissues at varyinglevels depending on cell type and developmental stage [239], with the
highest expression in the brain [240] correlating with the most active
period of myelination in rodents [64,241]. Human CTSDmRNA is trans-
lated into a 52 kDa proCTSD protein consisting of 462 amino acids
which undergoes several proteolytic processing steps during itsmatura-
tion and transport to endosomes and lysosomes [242,243]. In most spe-
cies, themature CTSD is composed of two polypeptides, light (97 amino
acids) and heavy chains (244 amino acids). Although the internal pro-
teolytic processing is not understood in detail, cysteine proteases are
likely to be involved [244]. CTSD maturation also involves N-linked gly-
cosylation at two asparagine residues, N134 andN263, andmodiﬁcation
with M6P-residues [71]. Depending on the cell type, however, varying
amounts of CTSD reach lysosomes viaM6P-dependent and independent
pathways [245–247].
11.2. CLN10 protein function and interactome
CTSD is a soluble lysosomal aspartyl endopeptidase that has been
implicated in several speciﬁc physiological functions, ranging from
proteolytic processing of selected polypeptides (hormones, growth
factors, cytokines, and enzymes), presenting brain antigens, degrada-
tion of cytoskeletal proteins to regulation of autophagy and apoptosis
[239,248–251]. Moreover, an enzymatically inactive CTSD mutant
(D231N) exhibit mitogenic activity and stimulate growth of normal
and cancer cells [252–254]. It appears that the enzymatic and mito-
genic activities of CTSD represent two independent functions of the
protein. Furthermore, evidence from cancer studies shows that in ad-
dition to the acidic milieu of lysosomes, cathepsin D may also func-
tion in other cellular compartments such as the extracellular matrix
or melanosomes [248,255,256], adding even more complexity to the
physiological functions of CTSD.
Protein–protein interaction databases (www.unihi.org, http://mint.
bio.uniroma2.it/mint/ and http://string-db.org) indicate that CTSD has
over 50 different interaction partners from various cellular compart-
ments, suggesting involvement in multiple cellular functions. The most
prominent of the CTSD interaction partners are amyloid beta (A4)
precursor protein (APP), cystatin C (CST3), thyroglobulin, the lysosomal
protease cathepsin B (CTSB) and prosaposin (proSAP), all of which
have been experimentally veriﬁed [257–261]. The physiological interac-
tion with APP provides a further link between CTSD and Alzheimer's
disease. Mechanistically APP may be involved in neurodegeneration
via its interaction with TNFRSF21, which triggers a caspase-dependent
self-destruction program involving caspase-3 (neuronal death) and
caspase-6 (axon pruning) [262]. CTSD-mediated cleavage of the cysteine
protease inhibitor CST3 might be physiologically important for indirect
regulation of CTSD activity through cysteine protease-dependent pro-
cessing, or activation of cysteine proteases [263]. Cleavage of the lyso-
somal prosaposin precursor protein into saposins A, B, C and D by
CTSD is essential for hydrolysis of certain sphingolipids [264]. Further
the interaction of CTSD with the ATP-binding cassette protein A1, the
highly elevated level of bis(monoacylglycero)phosphate (BMP) and
the altered phospholipid proﬁle in ctsd-deﬁcient brain suggest that
CTSD is involved in lipidmetabolism, and phospholipids and cholesterol
efﬂux [198,265].
Finally, thyroglobulin is a precursor of the iodinated thyroid
hormones thyroxine (T4) and triiodothyronine (T3) and CTSD ap-
pears to be involved in the proteolytic processing of these hor-
mones [266].
12. CLN11
12.1. CLN11/GRN gene and protein expression
Recently, homozygous mutations in the progranulin gene (GRN)
have been identiﬁed in two siblings with adult onset neuronal ceroid
lipofuscinosis [267]. The clinical phenotype of these patients differed
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totemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP).
GRN mRNA is widely expressed in epithelial cells, spleen, lymph
nodes, cells of the innate immune system, dorsal root and sympathic
ganglia of the peripheral nervous system, and in neuronal cells of
the neocortex, pyramidal and granule cells of hippocampus, ventro-
medial hypothalamus, Purkinje cells and in motor neurons [268–270].
GRN is also expressed inneuroinﬂammatorymicroglia but not in astroglia
or oligodendrocytes. The GRN gene encodes the secretory 88 kDa glyco-
protein progranulin (also known as proepithelin, acrogranin, granulin–
epithelin precursor) composed by 593 amino acids. Progranulin contains
a signal peptide and seven granulin-like domains forming four stacked
β-hairpins which are axially linked by six disulphide bridges [271].
After secretion the progranulin precursor protein is proteolytically
cleaved in the linker regions between the granulin domains by matrix
(MMP) and disintegrin metalloproteases (ADAM), and neutrophil-
secreted serine proteases (reviewed in [272]). The individual 6 kDa
cleavage products are called granulins A-G, but intermediate forms
are also detectable. Each granulin contains 12 highly conserved cysteine
consensus motifs except GRN G.
12.2. CLN11 protein function and interactome
The functions of progranulin and granulins are not known but
analyses of GRN-deﬁcient model organisms suggest important roles
in inﬂammation, early embryogenesis, cell motility, and tumorigene-
sis (reviewed by [273]) partially mediated via phosphatidylinositol-
3-kinase and extracellular signal responsive kinase (ERK1/2)
pathways [274]. Furthermore, progranulin exhibits neurotrophic or
neuroprotective effectsmost likely throughmodulation of survival signal-
ing (reviewed in [275]). In the brain of GRN-deﬁcient mice, microglial
activation, high level of ubiquitination, lipopigment storage, altered
synaptic connectivity and impaired synaptic plasticity have been
described [267,276,277].Weighted gene coexpression network anal-
ysis in GRN-deﬁcient human neurons revealed alterations in apopto-
tic, ubiquitination and Wnt-signaling pathways including upregulation
of the Wnt receptor Fzd2 that promotes neuronal survival [278].
Progranulins role in neuroinﬂammation ismost likely due to its binding
to tumor necrosis factor-α (TGFα) receptor 1 and 2 and the subsequent
inhibition of downstream TNFα signal transduction [279]. The other
known receptor that binds progranulin is the multi-ligand trans-
membrane protein sortilin, characterized to bind both neurotrophic fac-
tors [280,281] and to function as an alternative mannose 6-phosphate-
independent cargo receptor for lysosomal enzymes [282] and for the
endocytic regulation of the extracellular levels of secreted progranulin
[283] and its lysosomal delivery [284]. It remains to be studied whether
the secretion of mutant progranulin from activated microglia leads to
sortilin-mediated overloading of neuronal lysosomes with progranulin
polypeptides associated with an impaired transport of speciﬁc
lysosomal enzymes and subsequent lysosomal dysfunction causing
NCL.
On the cell surface of chondrocytes progranulin-interaction net-
workswithADAMTS-7, ADAMTS-12, the heparin sulphate proteoglycan
perlecan, HDL and the non-collagenous cartilage oligomericmatrix pro-
tein (COMP) has been reported (reviewed in [272,273]). It is likely
that complexes of progranulinwith components of the extracellularma-
trix may also play important roles in regulation of the activity and pro-
teolytic cleavage of progranulin in the brain.
13. CLN12
13.1. CLN12/ATP13A2 gene and protein expression
Mutations in ATP13A2 are a known cause of Kufor–Rakeb syndrome
(KRS), a rare form of autosomal recessive juvenile or early-onset,
levodopa-responsive migrostriatal–pallidal–pyramidal Parkinsonismand, as recently discovered, also of juvenile-onset NCL presenting with
learning difﬁculties [285–290]. Although the mutation in ATP13A2
gene was identiﬁed in a single NCL family, the discovery emphasizes
the partial phenotypic overlap between Parkinson's disease and NCLs,
particularly with CLN3 where Parkinsonian symptoms are always pres-
ent. Another link between ATP13A2 gene and NCLs was provided by a
study that identiﬁed a single-base deletion in ATP13A2 as the cause of
a well-established, late onset form of NCL in Tibetan terriers [291,292].
The CLN12 (ATP13A2) gene, also known as (KRPPD, PARK9, HSA9947,
RP-37C10.4) encodes a lysosomal type 5 P-type ATPase [289,293]
consisting of 1180 amino acid residues and 10 predicted transmem-
brane domains [294]. Cln12mRNA is transcribed into multiple variants
from which different protein isoforms are expressed. Cln12 transcripts
are ubiquitously expressed in most human tissues, with particularly
high levels in the brain. Dot blot analysis conﬁrmed the high expression
in fetal brain and various subregions of the adult brain, including
substantia nigra, hippocampus, cortex and thalamus [289].
13.2. CLN12 protein function and interactome
Although the function of the ATP13A2 protein remains unknown, it
has been suggested to regulate intracellular cation homeostasis and
neuronal integrity [295–298]. ATP12 has been suggested to protect
cells against α-synuclein misfolding and toxicity [295,299]. Moreover,
ATP13A2-defective human ﬁbroblasts and mouse primary neurons
show impaired lysosomal acidiﬁcation, decreased proteolytic pro-
cessing of lysosomal enzymes, reduced lysosomal degradation capacity,
and diminished lysosome-mediated clearance of autophagosomes [300,
301]. Lysosomal dysfunction in ATP13A2-defective cells appears to
impair α-synuclein degradation, and thus increase α-synuclein accu-
mulation and toxicity. Moreover, the data suggest that the modulation
of lysosomal ATP13A2 levels might be a putative therapeutic strategy
for CLN12.
In a recent study [299], the split ubiquitin membrane yeast two
hybrid system (MYTH) was used to determine 43 novel ATP13A2
interactors, most of which were implicated in endoplasmic reticulum
(ER) translocation, ER-to-Golgi trafﬁcking, and vesicular transport and
fusion. Six interactors, AAK1, HIPK1, NPY1R, YIF1A, HDAC6 and F2R,
are predicted to stimulateα-synucleinmisfolding, and seven interactors
were veriﬁed by co-immunoprecipitation. In addition, ATP13A2 has
been shown to bind CKLF-like MARVEL transmembrane domain-
containing protein 6 (CMTM6) and polyubiquitin-C (UBC) [302–305].
The physiological signiﬁcance of these ATP13A2–protein interactions
remains to be evaluated.
14. CLN13
14.1. CLN13 gene and protein expression
Mutations in the cathepsin F (CTSF, CLN13) gene have been recently
reported in 3 familieswith adult-onset NCL (Type B Kufs disease, [306]).
The slow progression rate of the disease is also observed in cathepsin
F-deﬁcient mice showing a late onset accumulation of autoﬂuorescent
lipofuscin throughout the CNS [307]. CTSF is transcribed into a 5.1 kb
mRNA, which is widely expressed in human tissues with high levels in
the heart, brain, skeletal muscle, testis, and ovary; whereas moderate
transcript expression was observed in the kidney, pancreas, placenta,
liver, and colon [308–311]. CTSF protein consists of 484 amino acids.
After cleavage of a 19 residue signal peptide CTSF is modiﬁed on oligo-
saccharides linked to N378 and N440 with M6P-residues [71]. CTSF be-
longs to a subgroup of cysteine proteases that contains a very long 251
amino acid propeptide encoding a cystatin-like domain which might
function as an endogenous cysteine protease inhibitor [309,311]. CTSF
is synthesized as an inactive preproenzyme that may be targeted to
the endosomal/lysosomal compartment via theM6P-receptor pathway.
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The physiological function of CTSF is still unclear; but analysis of
Ctsf-deﬁcientmice and in vitro studies indicated that this lysosomal cys-
teine protease is involved in degradation of class II-associated invariant
chain peptide andMHC class II peptide loading [312], lipoprotein degra-
dation, potentially linked to the formation of atherosclerotic lesions
[307,313,314], angiogenesis and tumor-associated inﬂammation [267].
Thus far, the only experimentally veriﬁed CLN13 interacting partner
is the CD74 antigen [312].15. CLN14 (KCTD7)
15.1. CLN14/KCTD7 gene and protein expression
The KCTD7 gene encodes the potassium channel tetramerization
domain-containing protein 7, also called CLN14. The KCTD7 transcripts
are ubiquitously expressed. In situ hybridization and immunohisto-
chemistry in murine brain demonstrated a strong Kctd7 expression in
the mitral cells of the olfactory bulb, the dentate gyrus and CA1–CA3
hippocampal cells, the deep layers of the cerebral cortex and the
Purkinje cells of the mouse cerebellum [315].
KCTD7 is a highly conserved protein of 289 amino acids that is
expressed in the brain as amajor 31 kDamonomeric and 62 kDa dimeric
polypeptide. Analysis of multiple tissues indicate strong tissue-speciﬁc
differences in the expression of KCTD7 [316]. The KCTD7 protein is locat-
ed in the cytoplasm with highest expression near the nucleus and a par-
tial localization at the plasma membrane [316]. Two phosphotyrosine
residues (Y162, Y163) have been identiﬁed in KCTD7 [317].15.2. CLN14/KCTD7 protein function and interactome
Overexpression of KCTD7 in murine neurons results in hyperpo-
larization of the resting membrane potential and decreases their ex-
citability in patch clamp experiments [315], suggesting that KCTD7
may function in modulating transporter subunits. The loss of KCTD7
expression is consistent with a depolarized resting membrane poten-
tial and increased excitability, which might be associated with an
epileptic phenotype of affected patients [315,318].
TheKCTD7protein contains anN-terminal domain comprising amino
acids 51–149 that is homologous to the T1 tetramerization domain found
in voltage-gated potassium channels and is part of a conserved protein–
protein interaction-domain family, the “Broad-complex, Tramtrack and
Bric a brac/Pox virus and Zinc ﬁnger” (BTB/POZ) domain family. The
BTB/POZ domains are found in a number of proteins with various func-
tions, including transcriptional regulation, cytoskeleton dynamics, ion
channel assembly and gating, and targeting of proteins for ubiquitination
[319].
Similar to other members of the KCTD family [218,320], KCTD7 has
been shown to interact with cullin-3, a component of E3 ubiquitin–
protein ligases that selectively modify proteins for degradation at the
proteasome [315]. The KCTD7/cullin-3 interaction is mediated, at least
in part, through the BTB/ZOB domain. KCTD7 itself is not ubiquinated
[315] and might modulate the ubiquitination of other yet unidentiﬁed
cullin-3 substrates. The ubiquitination of transmembrane ion channels
is a frequently observed mechanism regulating their cell membrane
expression [321–323]. The pathogenic NCL-mutation KCTD7(p.R184C)
results in an alteration of the subcellular localization of theKCTD7protein
and disrupts its interactionwith cullin-3 [316]whichmight lead to an ac-
cumulation of substrate proteins designated for lysosomal destination
and dysregulation of protein-degradation mechanisms within the cell.
The amount of KCTD7 protein was found to be elevated in cerebellar
granule cells derived from a murine JNCL model (CbCln3Δex7/8/Δex7/8)
suggesting an impact of CLN3 deﬁciency on KCTD7 turnover [316].16. Concluding remarks
Although exom sequencing in families with NCL phenotype of un-
known origin, as well as multiple sensitive biochemical and proteo-
mic approaches led to the identiﬁcation of novel NCL-causing gene
defects in the last years, many important issues in the elucidation of
the pathogenic mechanisms of neurodegeneration in NCL remain
unsolved. For example, despite the identiﬁcation of more than 200 ly-
sosomal M6P-containing soluble and membrane proteins [324], the
majority of these proteins are functionally not characterized. It also re-
mains to be further examined whether defective endosomal/lysosomal
chloride exchanger CLC-6 and CLC-7 display some NCL-like features
[6,325], and represent candidates of this group of diseases. Another
very interesting issue concerns genenetworks regulating lysosomal bio-
genesis and function. Indeed, several lysosomal genes including CLN1,
CLN2, CLN3, CLN5, CLN7, CLN10 andCLN13have been identiﬁed as poten-
tial targets for the master gene transcription factor EB (TFEB; [326])
that regulates the coordinated transcription of genes encoding lyso-
somal proteins involved in degradation of proteins, glycosaminogly-
cans, sphingolipids and glycogen [327]. Additionally, TFEB targets are
genes associated with autophagy, exo- and endocytosis, phagocytosis
and immune response. Therefore, the TFEB gene network might be a
therapeutic target to prevent neurotoxic accumulation of storagemate-
rial in NCL diseases. The continued development of new molecular and
sensitive tools as well as advances in instrumentation will provide in-
sight into these unresolved issues in the not too distant future.
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